The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
MASSIVE day, huge license deals will be announced, ava3996 will have been secretly been in trials and sales of 90 billion will be announced. Share price will be £200 ex chi-nah. Can't wait!!!!
Or like every other meeting that's built up as a massive crescendo of news, nothing will happen (apart from results ) and the SP will be the same.
And so the circle of fud continues
https://wondermark.com/c/1062/
You could try clinicaltrials@avacta.com
https://avacta.com/clinical-trials/
Even if they do get rid of DX they will keep affimers. Will just be as before designing affimer for clients like with affyxcell.
And one of the new pre|CISION products also utilises affimer.
On a side note does that mean TMAC shelved?